SELLAS Life Sciences reported on November 17 that its Phase 3 REGAL trial met its primary overall survival endpoint in acute myeloid leukemia. Median survival was 24.0 months for patients who received galinpepimut-S and 14.7 months for those on best available treatment, a difference of 9.3 months. The hazard ratio was 0.59, which corresponds to a 41 percent reduction in the risk of death, with a two-sided p value of 0.035.
The result is the strongest late-stage readout a cancer vaccine has produced in this disease. It is also a topline announcement, open-label, and not yet peer-reviewed. Those qualifications do not cancel the survival difference. They define what the difference can and cannot support.
The result
The trial enrolled 126 patients and randomized them one to one. The analysis was triggered after the prespecified 80 deaths. The primary endpoint was overall survival, and the company says the result was statistically significant and clinically meaningful.
The patient population is narrow and difficult. REGAL enrolled patients with acute myeloid leukemia in second or later complete remission, including complete remission with incomplete platelet recovery, after at least second-line salvage therapy. The patients were not eligible for, or could not undergo, an allogeneic stem cell transplant.
That is a group with few good options. Allogeneic transplant is the curative-intent path for many AML patients, and a patient who cannot receive one is usually managed with lower-intensity therapy and watched closely. A therapy that extends median survival by nine months in that setting would matter to patients and clinicians, if it holds up. Those patients are usually older or have comorbidities that make transplant unsafe. The standard of care for them is not a single regimen. It is a sequence of lower-intensity options chosen for the individual patient, and the median survival is measured in months. That is the baseline against which a 9.3-month median improvement should be read.
What the trial measured
Galinpepimut-S is a WT1-targeted peptide vaccine. WT1 is a protein that is overexpressed in several cancers, including AML, and the vaccine is designed to train the immune system to attack cells that present it. It is an off-the-shelf product, not a patient-specific therapy, which matters for manufacturing and for how quickly it could reach patients if approved.
The vaccine was licensed from Memorial Sloan Kettering, where it was invented in the lab of David Scheinberg. MSK's news release describes the result as a survival benefit for people with AML and notes the vaccine's long development history.
The control arm is where the trial's design gets complicated. Patients on the comparator received their investigator's choice of observation, a hypomethylating agent, venetoclax, or low-dose cytarabine. Those are not equivalent treatments. The control arm is a mix of active therapy and watchful waiting, and the mix is chosen by the treating investigator.
The trial was open-label, meaning patients and investigators knew who received the vaccine. Open-label trials are common in oncology, and they are also a source of bias in endpoints that depend on judgment. Overall survival is the least subjective endpoint available, which is the strongest argument for the result. The concern shifts to the control arm and to whether the two groups were balanced at baseline.
The company says the vaccine was generally well tolerated, with mostly Grade 1 or 2 treatment-related adverse events, most commonly injection-site reactions. No new safety signals were reported.
What the vaccine is
WT1 is not a new target. It has been studied in cancer vaccines for decades, and the field has produced many immunological responses that did not translate into survival benefits. That history is why the REGAL result is being treated as a milestone. A vaccine that generates an immune response is a laboratory finding. A vaccine that extends survival in a randomized Phase 3 trial is a clinical finding.
The off-the-shelf design is also commercially important. Patient-specific vaccines require a manufacturing chain tied to each patient, with the associated cost and delay. A product that can be manufactured in batches and shipped is easier to scale, easier to price, and easier to deliver in community oncology settings.
The tradeoff is that a shared antigen target may be less precise than a personalized neoantigen vaccine. The immune system has to recognize WT1 on tumor cells without doing unacceptable damage elsewhere. The safety data in this trial suggest the approach was tolerable in this population. Longer follow-up will show whether that holds. The WT1 field also has a long record of immunological signals that did not become survival benefits. That history is why a randomized overall survival result carries more weight than a response rate, and why the full data and the confirmatory follow-up will be scrutinized.
The regulatory path
SELLAS plans to meet with the FDA to discuss an accelerated filing strategy, according to the company and trade coverage. It is targeting a biologics license application submission in the first half of 2027, with secondary analyses ongoing and full data to be presented at a future medical conference and submitted for peer-reviewed publication.
An accelerated approval in oncology typically relies on a surrogate endpoint, often response rate or event-free survival, with a confirmatory trial to follow. Overall survival is the gold standard, and a positive overall survival result is a stronger basis for a filing than a surrogate. The question is whether the FDA will accept the trial's design, the control arm, and the topline data as sufficient, or whether it will want a confirmatory study or a longer follow-up.
The company's reference to an accelerated strategy suggests it is looking for a faster path. The market reaction was immediate, with the stock more than doubling on the news. A full approval based on overall survival would be a higher bar and a longer timeline. The difference matters for patients and investors, and it will not be settled until the FDA meeting and the full data are public.
What the topline does not show
The announcement does not include a confidence interval for the hazard ratio. That is a notable omission. A point estimate of 0.59 with a wide confidence interval and one with a narrow interval tell different stories, and the p value alone does not convey the precision.
The full data will also need to show whether the survival curves separate early or late, whether the benefit holds across subgroups, and whether the control arm's composition affected the result. A control arm that includes observation and low-dose cytarabine is not the same comparator as a control arm that includes venetoclax for every patient. The mix matters.
The result is also topline and unpeer-reviewed. That is normal for a company announcement, and it is not evidence of a problem. It does mean the independent review, the complete data, and the conference presentation are still ahead. One trial is one trial. A positive result in a 126-patient study needs to be replicated or confirmed in a larger population before it becomes a standard of care, and the FDA's view of the control arm will shape whether the current data are enough for a filing.
What patients and clinicians should take from it
The result is encouraging for a population with limited options. It is not a reason to change practice today. Galinpepimut-S is not approved, the data are not fully published, and the regulatory path is not settled.
Patients with AML in second or later remission who are not eligible for transplant should talk with their care team about clinical trials and about what the REGAL result might mean for future options. The vaccine is not available outside a trial or a company access program, and the full data will take time to arrive.
The broader lesson is about the vaccine field. For years, cancer vaccines have been long on immune responses and short on survival. A positive Phase 3 overall survival result is the kind of evidence the field has been waiting for. The next step is the least glamorous one: the full data, the peer review, and the FDA review.
Primary sources
- SELLAS Life Sciences for the topline REGAL results and the regulatory plans.
- Memorial Sloan Kettering Cancer Center for the vaccine's origin and the trial result.
- BioPharm International for the trial design and the data.
- BioSpace for the hazard ratio and the stock reaction.
- Drug Delivery and Development for the FDA discussion and the BLA timeline.
- Yahoo Finance for the market reaction.